Brief: Nanobiotix End-Dec Estimated Cash Position At Around EUR 83.9 Mln

Nanobiotix SA

10/01/2022 09:58

Jan 10 (Reuters) - Nanobiotix SA  NANOB.PA :
    * PROVIDES CORPORATE UPDATE AND HIGHLIGHTS KEY 2022
MILESTONE
TARGETS
    * OPERATING RUNWAY EXTENDED INTO Q2 2023 AS A RESULT OF
ENHANCING
OPERATIONAL EFFICIENCIES AND OPTIMIZING CAPITAL ALLOCATION FOR
CONTINUED INVESTMENT IN PRIORITY DEVELOPMENT PATHWAYS
    * AS OF DECEMBER 31, 2021, NANOBIOTIX ESTIMATES THAT IT HAD
APPROXIMATELY EUR 83.9 MILLION IN CASH, CASH EQUIVALENTS, AND
INVESTMENTS, COMPARED TO EUR 119.2 MILLION AS OF DECEMBER 31,
2020
    * IN 2022, NANOBIOTIX PLANS TO CONTINUE TO GROW AND
STRENGTHEN ITS
ORGANIZATIONAL CAPABILITIES IN ORDER TO DELIVER ON POTENTIAL OF
ITS LEAD PRODUCT CANDIDATE, NBTXR3
    * PRIORITY NBTXR3 PLUS ANTI-PD-1 COMBINATION PROGRAM POISED
TO
ADVANCE AS COMPANY SEEKS TO DEFINE REGISTRATION PATHWAY WITH
REGULATORY AGENCIES BASED ON INITIAL DATA FROM ONGOING PHASE I
IMMUNOTHERAPY STUDY
    * EVALUATION OF NBTXR3 FOR GLOBAL REGISTRATION IN PRIORITY
HEAD
AND NECK CANCER PATHWAY PROCEEDS WITH FIRST EUROPEAN PATIENT
RANDOMIZED IN GLOBAL PHASE III NANORAY-312 STUDY; US AND ASIA
SITE ACTIVATION EXPECTED IN 2022
    * IN 2022, NANOBIOTIX DEVELOPMENT PROGRAM WILL CONTINUE TO
FOCUS
ON: (I) EXECUTION OF COMPANY-LED PRIORITY PATHWAYS IN HNSCC AND
IMMUNOTHERAPY, AND (II) WORKING WITH EXISTING AND FUTURE
COLLABORATORS TO EXPAND DEVELOPMENT FOOTPRINT FOR NBTXR3
    * NOW EXPECTS THAT ITS CASH, CASH EQUIVALENTS, AND
INVESTMENTS AS
OF DECEMBER 31, 2021 WILL ENABLE COMPANY TO FUND ITS CURRENT
OPERATIONAL PLAN INTO Q2 OF 2023

Source text for Eikon:  ID:nBw2WwQm6a 
Further company coverage:  NANOB.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))